Response to ASX Aware Letter

Summary by 6ix AI

Lumos Diagnostics Holdings Limited has submitted a response to an ASX Aware Letter regarding its trading halt and subsequent announcements related to FDA correspondence for its product FebriDx. The company confirms it first became aware of the relevant information on a specific date and time, prompting a trading halt to assess the implications before making a public announcement. Lumos asserts compliance with ASX Listing Rules, stating that it acted promptly in disclosing the information once it was no longer confidential. The filing outlines the company's internal processes for reviewing FDA correspondence and preparing market announcements to ensure accurate and complete disclosure.

Written by 6ix AI from the company’s filing. How 6ix writes summaries